After completing the above evaluation, the R&D team will have multi-dimensional data. Below is an overview of the core dimensions in the GeneMedi TCE evaluation system:
| # | Evaluation Dimension | Core Question | Representative Metrics | Typical Blinatumomab Range |
|---|---|---|---|---|
| 1 | Target-antigen expression | Is the target correctly expressed? | Antigen density (ABC, quantitative) | CD19⁺ Raji 2–3 orders of magnitude above negative (recorded as ABC) [1] |
| 2 | T-cell composition | Is the effector population well-defined? | CD3 / CD4 / CD8 | CD3⁺ >95%; CD4/CD8 ≈ 1.5–2.5 [1][3] |
| 3 | T-cell activation | Is reasonable activation produced? | RGA EC₅₀/Emax; CD69 (4–6 h) / CD25 / 4-1BB / OX40 | CD69 EC₅₀ 0.5–2 ng/mL; Emax 60–80% of upper-limit control [3] |
| 4 | Cytotoxicity | Is killing effective and target-dependent? | EC₅₀ / Emax / T₅₀ / AUC | EC₅₀ 10–50 pM; Emax 80–95%; CD19⁻ <10% [1][2] |
| 5 | Effector function | Do T cells execute killing? | CD107a + granzyme B | CD107a⁺ CD8⁺ proportion 30–60% [1] |
| 6 | Cytokine release | Is there excessive immune activation? | 9–13-plex panel (incl. GM-CSF) | IL-6 peak 500–3000 pg/mL, below high-CRS positive control [2][3] |
| 7 | Functional durability | Is function sustained? | Re-stimulation retention + per-round expansion + Tpex/Tex ratio + K₁/₂; inhibitory receptors | Post-re-stimulation killing retention 50–70% (internal reference) |
| 8 | Reference benchmark | How does the candidate compare? | Relative performance | Benchmarked against the blinatumomab historical database |
| 9 | In vitro therapeutic index | How wide is the dose separation between efficacy and cytokines? | TI = cytokine EC₅₀ ÷ killing EC₅₀ | Benchmarked by this system's historical database |
In vitro therapeutic index: Within a single candidate, the separation between the killing dose-response and the cytokine dose-response is the most direct safety-window metric. Define TI = EC₅₀ for IL-6 (or TNF-α) release ÷ EC₅₀ for target-cell killing — the larger the TI, the higher the dose required to trigger cytokines relative to efficacy, and the wider the safety window. Ultimately, these data transform from "experimental readouts" into an integrated TCE candidate profile: efficacy × target selectivity × controlled immune activation × functional durability.
Identify the most advancement-worthy candidate from multiple molecules. The ranking strategy is: first eliminate molecules that are binding-negative, under-activated, weakly cytotoxic, or have abnormal cytokine release; then weight-score the remaining molecules by killing capacity and safety, selecting the top 1–5 for deeper validation.
